HK Stock Market Move | CSPC PHARMA (01093) rises over 4%; net profit for the first three quarters more than doubles year-on-year; licensing fee revenue surges 307%

date
10:51 19/11/2026
avatar
GMT Eight
CSPC PHARMA (01093) rose over 4%. As of press time, it was up 4.13% at HK$8.315, with a turnover of HK$389 million.
CSPC PHARMA (01093) rose over 4%, up 4.13% as of press time at HK$8.315, with turnover of HK$389 million. On the news front, CSPC PHARMA released its third-quarter results yesterday. For the first three quarters, the company recorded revenue of RMB25.26 billion, up 27.0% year-on-year; profit attributable to owners of the company was RMB7.076 billion, up 101.5% year-on-year. Specifically, CSPC PHARMA had approximately RMB6.268 billion in licensing fee revenue in the first three quarters, up 307% from RMB1.54 billion in the same period last year, ultimately driving overall growth of the finished drug business of 40.1% to RMB21.648 billion. Huatai noted that looking ahead to 2026-2027, it is optimistic about positive organic profit growth in 2026, with BD significantly boosting reported figures. In 2027, based on no price cut in the NBP renewal, volume ramp-up of newly NRDL-included products such as albumin-bound paclitaxel II and KN026, and the launch of sirolimus albumin and EGFR ADC, organic profit is expected to maintain positive growth. Coupled with the realization of multiple subsequent milestones and the potential overseas expansion of pipeline products, the "Buy" rating is maintained.